Suppr超能文献

欧洲各地门诊肾病诊所慢性肾脏病患者的进展和死亡率不同。

Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe.

机构信息

ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.

ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.

出版信息

Kidney Int. 2018 Jun;93(6):1432-1441. doi: 10.1016/j.kint.2018.01.008. Epub 2018 Apr 12.

Abstract

The incidence of renal replacement therapy varies across countries. However, little is known about the epidemiology of chronic kidney disease (CKD) outcomes. Here we describe progression and mortality risk of patients with CKD but not on renal replacement therapy at outpatient nephrology clinics across Europe using individual data from nine CKD cohorts participating in the European CKD Burden Consortium. A joint model assessed the mean change in estimated glomerular filtration rate (eGFR) and mortality risk simultaneously, thereby accounting for mortality risk when estimating eGFR decline and vice versa, while also correcting for the measurement error in eGFR. Results were adjusted for important risk factors (baseline eGFR, age, sex, albuminuria, primary renal disease, diabetes, hypertension, obesity and smoking) in 27,771 patients from five countries. The adjusted mean annual eGFR decline varied from 0.77 (95% confidence interval 0.45, 1.08) ml/min/1.73m in the Belgium cohort to 2.43 (2.11, 2.75) ml/min/1.73m in the Spanish cohort. As compared to the Italian PIRP cohort, the adjusted mortality hazard ratio varied from 0.22 (0.11, 0.43) in the London LACKABO cohort to 1.30 (1.13, 1.49) in the English CRISIS cohort. These results suggest that the eGFR decline showed minor variation but mortality showed the most variation. Thus, different health care organization systems are potentially associated with differences in outcome of patients with CKD within Europe. These results can be used by policy makers to plan resources on a regional, national and European level.

摘要

肾替代治疗的发病率在各国之间存在差异。然而,对于慢性肾脏病(CKD)结局的流行病学情况知之甚少。在这里,我们使用参与欧洲 CKD 负担联合会的九个 CKD 队列的个体数据,描述了在欧洲各地的门诊肾病诊所中未接受肾替代治疗的 CKD 患者的进展和死亡风险。联合模型同时评估了估算肾小球滤过率(eGFR)的平均变化和死亡风险,从而在估计 eGFR 下降时考虑了死亡风险,反之亦然,同时还校正了 eGFR 的测量误差。结果在五个国家的 27771 名患者中进行了重要风险因素(基线 eGFR、年龄、性别、白蛋白尿、原发性肾脏疾病、糖尿病、高血压、肥胖和吸烟)的调整。调整后的平均每年 eGFR 下降范围从比利时队列的 0.77(95%置信区间 0.45,1.08)ml/min/1.73m 到西班牙队列的 2.43(2.11,2.75)ml/min/1.73m。与意大利 PIRP 队列相比,调整后的死亡率风险比在伦敦 LACKABO 队列中从 0.22(0.11,0.43)变化到在英国 CRISIS 队列中为 1.30(1.13,1.49)。这些结果表明,eGFR 下降变化较小,但死亡率变化最大。因此,不同的医疗保健组织系统可能与欧洲范围内 CKD 患者的结局差异相关。这些结果可被决策者用于在区域、国家和欧洲层面规划资源。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验